PE20151295A1 - Derivado de hidantoina - Google Patents
Derivado de hidantoinaInfo
- Publication number
- PE20151295A1 PE20151295A1 PE2015000878A PE2015000878A PE20151295A1 PE 20151295 A1 PE20151295 A1 PE 20151295A1 PE 2015000878 A PE2015000878 A PE 2015000878A PE 2015000878 A PE2015000878 A PE 2015000878A PE 20151295 A1 PE20151295 A1 PE 20151295A1
- Authority
- PE
- Peru
- Prior art keywords
- atoms
- substitute
- optionally substituted
- independently
- hydantoin derivative
- Prior art date
Links
- WJRBRSLFGCUECM-UHFFFAOYSA-N hydantoin Chemical class O=C1CNC(=O)N1 WJRBRSLFGCUECM-UHFFFAOYSA-N 0.000 title abstract 2
- 102000003982 Parathyroid hormone Human genes 0.000 abstract 2
- 108090000445 Parathyroid hormone Proteins 0.000 abstract 2
- 239000000199 parathyroid hormone Substances 0.000 abstract 2
- 229960001319 parathyroid hormone Drugs 0.000 abstract 2
- 208000000038 Hypoparathyroidism Diseases 0.000 abstract 1
- 229940053195 antiepileptics hydantoin derivative Drugs 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 229910052736 halogen Inorganic materials 0.000 abstract 1
- 150000002367 halogens Chemical class 0.000 abstract 1
- WCYWZMWISLQXQU-UHFFFAOYSA-N methyl Chemical group [CH3] WCYWZMWISLQXQU-UHFFFAOYSA-N 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/438—The ring being spiro-condensed with carbocyclic or heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
SE REFIERE A DERIVADOS DE HIDANTOINA DE FORMULA (1) Y SUS SALES FARMACOLOGICAMENTE ACEPTABLES, EN DONDE R1 Y R2 SON INDEPENDIENTEMENTE H, HALOGENO, ALQUILO C1-C2 OPCIONALMENTE SUSTITUIDO CON 1 A 5 ATOMOS DE F, O ALCOXI C1-C2 OPCIONALMENTE SUSTITUIDO CON 1 A 5 ATOMOS DE F, CON LA CONDICION DE QUE R1 Y R2 NO SON AMBOS H; O R1 Y R2 JUNTOS FORMAN -O-CF2-O-; R3 Y R4 SON INDEPENDIENTEMENTE METILO OPCIONALMENTE SUSTITUIDO CON 1 A 3 ATOMOS DE F; O -CR3R4- FORMAN UN ANILLO CARBOCICLICO C3-C6 (EN EL CUAL UNO DE LOS ATOMOS DE C DEL ANILLO CARBOCICLICO PUEDE ESTAR REEMPLAZADO CON O, S, N o N-CH3). DICHOS COMPUESTOS TIENEN FUERTES EFECTOS SIMILARES A LOS DE LA HORMONA PARATIROIDEA (PTH), POR LO CUAL SON UTILES EN EL TRATAMIENTO DE CONDICIONES PATOLOGICAS TALES COMO EL HIPOPARATIROIDISMO
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2012269178 | 2012-12-10 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PE20151295A1 true PE20151295A1 (es) | 2015-10-10 |
Family
ID=50934349
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PE2015000878A PE20151295A1 (es) | 2012-12-10 | 2013-12-10 | Derivado de hidantoina |
Country Status (34)
| Country | Link |
|---|---|
| US (5) | US9428505B2 (es) |
| EP (1) | EP2930176B1 (es) |
| JP (1) | JP5951799B2 (es) |
| KR (1) | KR102168738B1 (es) |
| CN (1) | CN104854106B (es) |
| AU (1) | AU2013358167B2 (es) |
| BR (1) | BR112015012411B1 (es) |
| CA (1) | CA2892621C (es) |
| CL (2) | CL2015001391A1 (es) |
| CR (1) | CR20150272A (es) |
| DK (1) | DK2930176T3 (es) |
| ES (1) | ES2663797T3 (es) |
| HR (1) | HRP20180647T1 (es) |
| HU (1) | HUE037530T2 (es) |
| IL (1) | IL238277B (es) |
| LT (1) | LT2930176T (es) |
| MA (1) | MA38250B1 (es) |
| MX (1) | MX2015007309A (es) |
| MY (1) | MY178583A (es) |
| NO (1) | NO2930176T3 (es) |
| NZ (1) | NZ707946A (es) |
| PE (1) | PE20151295A1 (es) |
| PH (1) | PH12015501146B1 (es) |
| PL (1) | PL2930176T3 (es) |
| PT (1) | PT2930176T (es) |
| RS (1) | RS57190B1 (es) |
| RU (1) | RU2678984C2 (es) |
| SA (1) | SA515360528B1 (es) |
| SG (1) | SG11201504204XA (es) |
| SI (1) | SI2930176T1 (es) |
| TW (1) | TWI615394B (es) |
| UA (1) | UA115072C2 (es) |
| WO (1) | WO2014092061A1 (es) |
| ZA (1) | ZA201503597B (es) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2010126030A1 (ja) | 2009-04-28 | 2010-11-04 | 中外製薬株式会社 | スピロイミダゾロン誘導体 |
| NO2930176T3 (es) * | 2012-12-10 | 2018-07-07 | ||
| RU2701168C2 (ru) * | 2014-06-09 | 2019-09-25 | Чугаи Сейяку Кабусики Кайся | Фармацевтическая композиция, содержащая производные гидантоина |
| EP3831381A4 (en) | 2018-07-30 | 2022-05-04 | Chugai Seiyaku Kabushiki Kaisha | SOLID DISPERSION OF A HYDANTOIND DERIVATIVE |
| CN110464002A (zh) * | 2019-09-12 | 2019-11-19 | 西南石油大学 | 一种天然冰粉的制备方法及其应用 |
| JPWO2024143501A1 (es) | 2022-12-28 | 2024-07-04 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH1135470A (ja) | 1997-07-23 | 1999-02-09 | Teijin Ltd | ビタミンｄ３誘導体を含有する副甲状腺ホルモン産生促進剤 |
| CN1132819C (zh) | 1998-12-11 | 2003-12-31 | 霍夫曼-拉罗奇有限公司 | 作为TNF－α抑制剂的环状肼衍生物 |
| CA2420759A1 (en) | 2000-08-30 | 2003-02-27 | Daishiro Miura | Parathyroid hormone production inhibitors containing vitamin d3 derivatives |
| CA2425283A1 (en) * | 2000-10-26 | 2002-05-02 | Pfizer Products Inc. | Spiro-pyrimidine-2,4,6-trione metalloproteinase inhibitors |
| SE0100902D0 (sv) | 2001-03-15 | 2001-03-15 | Astrazeneca Ab | Compounds |
| AR038658A1 (es) | 2001-06-15 | 2005-01-26 | Novartis Ag | Derivados de 4-aril-2(1h) quinazolinona y 4-aril-quinazolina 2-sustituidas, un proceso para su preparacion, composiciones farmaceuticas y el uso de dichos derivados para la preparacion de un medicamento |
| AU2003237424A1 (en) * | 2002-06-06 | 2003-12-22 | Donnelly Corporation | Interior rearview mirror system with compass |
| EP1713782A4 (en) | 2004-02-11 | 2009-11-11 | Smithkline Beecham Corp | PTH AGONISTS |
| WO2005077959A1 (en) | 2004-02-11 | 2005-08-25 | Smithkline Beecham Corporation | Pth agonists |
| CN101072771B (zh) | 2004-10-07 | 2010-09-29 | 默沙东公司 | Cgrp受体拮抗剂 |
| WO2007135417A1 (en) | 2006-05-19 | 2007-11-29 | James Black Foundation | Benzotriazepinone derivatives |
| MX2008016273A (es) | 2006-06-20 | 2009-01-15 | Wyeth Corp | Inhibidores de canal de potasio kv1.5. |
| ES2351378T3 (es) | 2007-06-07 | 2011-02-03 | F. Hoffmann-La Roche Ag | Derivados de prolinamida como antagonistas de nk3. |
| PT2444120T (pt) | 2007-12-10 | 2018-01-03 | Novartis Ag | Análogos da amilorida espirocíclicos como bloqueadores de enac |
| US7981904B2 (en) | 2008-03-20 | 2011-07-19 | Takeda Pharmaceutical Company Limited | Acetyl CoA carboxylase inhibitors |
| US8513193B2 (en) | 2008-10-13 | 2013-08-20 | University Of Rochester | Protecting and repairing cartilage and musculoskeletal soft tissues |
| WO2010126030A1 (ja) | 2009-04-28 | 2010-11-04 | 中外製薬株式会社 | スピロイミダゾロン誘導体 |
| NO2930176T3 (es) * | 2012-12-10 | 2018-07-07 | ||
| RU2701168C2 (ru) * | 2014-06-09 | 2019-09-25 | Чугаи Сейяку Кабусики Кайся | Фармацевтическая композиция, содержащая производные гидантоина |
-
2013
- 2013-12-10 NO NO13862318A patent/NO2930176T3/no unknown
- 2013-12-10 LT LTEP13862318.6T patent/LT2930176T/lt unknown
- 2013-12-10 MA MA38250A patent/MA38250B1/fr unknown
- 2013-12-10 JP JP2014552040A patent/JP5951799B2/ja active Active
- 2013-12-10 AU AU2013358167A patent/AU2013358167B2/en not_active Ceased
- 2013-12-10 MX MX2015007309A patent/MX2015007309A/es active IP Right Grant
- 2013-12-10 MY MYPI2015701868A patent/MY178583A/en unknown
- 2013-12-10 CN CN201380064459.1A patent/CN104854106B/zh not_active Expired - Fee Related
- 2013-12-10 BR BR112015012411-9A patent/BR112015012411B1/pt not_active IP Right Cessation
- 2013-12-10 ES ES13862318.6T patent/ES2663797T3/es active Active
- 2013-12-10 PE PE2015000878A patent/PE20151295A1/es active IP Right Grant
- 2013-12-10 PT PT138623186T patent/PT2930176T/pt unknown
- 2013-12-10 SG SG11201504204XA patent/SG11201504204XA/en unknown
- 2013-12-10 RS RS20180517A patent/RS57190B1/sr unknown
- 2013-12-10 EP EP13862318.6A patent/EP2930176B1/en active Active
- 2013-12-10 CA CA2892621A patent/CA2892621C/en active Active
- 2013-12-10 HR HRP20180647TT patent/HRP20180647T1/hr unknown
- 2013-12-10 WO PCT/JP2013/083022 patent/WO2014092061A1/ja not_active Ceased
- 2013-12-10 KR KR1020157017844A patent/KR102168738B1/ko not_active Expired - Fee Related
- 2013-12-10 TW TW102145318A patent/TWI615394B/zh not_active IP Right Cessation
- 2013-12-10 SI SI201331009T patent/SI2930176T1/en unknown
- 2013-12-10 NZ NZ70794613A patent/NZ707946A/en not_active IP Right Cessation
- 2013-12-10 RU RU2015127624A patent/RU2678984C2/ru active
- 2013-12-10 DK DK13862318.6T patent/DK2930176T3/en active
- 2013-12-10 UA UAA201504548A patent/UA115072C2/uk unknown
- 2013-12-10 US US14/426,408 patent/US9428505B2/en active Active
- 2013-12-10 HU HUE13862318A patent/HUE037530T2/hu unknown
- 2013-12-10 PL PL13862318T patent/PL2930176T3/pl unknown
-
2015
- 2015-04-14 IL IL238277A patent/IL238277B/en active IP Right Grant
- 2015-05-21 CR CR20150272A patent/CR20150272A/es unknown
- 2015-05-21 ZA ZA2015/03597A patent/ZA201503597B/en unknown
- 2015-05-22 CL CL2015001391A patent/CL2015001391A1/es unknown
- 2015-05-22 PH PH12015501146A patent/PH12015501146B1/en unknown
- 2015-06-04 SA SA515360528A patent/SA515360528B1/ar unknown
-
2016
- 2016-07-20 US US15/214,729 patent/US20160326175A1/en not_active Abandoned
-
2017
- 2017-01-11 CL CL2017000069A patent/CL2017000069A1/es unknown
- 2017-12-20 US US15/848,267 patent/US20180237436A1/en not_active Abandoned
-
2020
- 2020-02-28 US US16/805,204 patent/US20210024524A1/en not_active Abandoned
-
2021
- 2021-05-25 US US17/330,200 patent/US20220162208A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CU24605B1 (es) | Pirimidin-2-il amino-1h-pirazoles útiles como inhibidores de lrrk2 | |
| CR20200276A (es) | Sulfamoilarilamidas y su uso como medicamentos para el tratamientos de la hepatitis b (divisional exp. 2015-0059) | |
| DOP2017000149A (es) | Compuestos de triazolopirimidina y usos de los mismos | |
| CU24517B1 (es) | Derivados de carbonucleósidos sustituidos útiles como agentes antineoplásicos | |
| CL2017003032A1 (es) | Derivado de pirido[3,4-d]pirimidina y sal farmacéuticamente aceptable de éste | |
| UY36056A (es) | “compuestos de heteroarilo o arilo bicíclicos fusionados “. | |
| MX2018002402A (es) | Compuestos de heteroarilo o arilo biciclicos fusionados como moduladores de la quinasa 4 asociada al receptor de la interleucina 1 (irak4). | |
| PE20151295A1 (es) | Derivado de hidantoina | |
| CU20170073A7 (es) | Compuestos de indazol sustituidos y compuestos intermediarios para la preparación de los mismos | |
| CR20150472A (es) | USO DE DERIVADOS DE PIRAZOLOPIRIMIDINA PARA EL TRATAMIENTO DE TRANSTORNOS RELACIONADOS CON LA PI3Kd | |
| EA201500875A1 (ru) | СОЛИ ПРОИЗВОДНЫХ 2-АМИНО-1-ГИДРОКСИЭТИЛ-8-ГИДРОКСИХИНОЛИН-2-(1Н)-ОНА, ОБЛАДАЮЩИЕ АГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К β2 АДРЕНЕРГИЧЕСКОМУ РЕЦЕПТОРУ И АНТАГОНИСТИЧЕСКОЙ АКТИВНОСТЬЮ ПО ОТНОШЕНИЮ К МУСКАРИНОВОМУ РЕЦЕПТОРУ М3 | |
| MX2015006039A (es) | Derivados de pirimidin-2, 4-diamina para el tratamiento de cancer. | |
| PE20160862A1 (es) | Polimorfo de los inhibidores de la syk | |
| MX395458B (es) | Metodos novedosos | |
| DOP2016000242A (es) | Uso de compuestos heterocíclicos para controlar nematodos | |
| UY35916A (es) | Compuestos tricíclicos como agentes antineoplásicos inhibidores del bromodominio | |
| NI201200192A (es) | Derivados de imidazopiridina, su procedimiento de preparación y su aplicación en terapéutica. | |
| CR20130369A (es) | Novedosos derivados heterocíclicos | |
| UY34305A (es) | Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar | |
| UY35333A (es) | Compuestos de azabencimidazol | |
| EA201791058A1 (ru) | Морфолин- и 1,4-оксазепан-амиды в качестве агонистов соматостатинового рецептора подтипа 4 (sstr4) | |
| MX2018001992A (es) | Compuestos triciclicos heterociclicos como inhibidores de fosfoinositol 3-quinasa. | |
| MX2015014757A (es) | Derivados de purina como agonistas del receptor de cannabinoides 2 (cb2). | |
| PE20141940A1 (es) | Compuestos triciclicos, composiciones que los comprenden y usos de los mismos | |
| CR20160448A (es) | Nuevos derivados de piridina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |